Please Wait...

Biomarkers and Personalized Medicine: Essential Tools

The use of biomarkers is expanding across all stages in the drug development process, helping bring about new and innovative practices in the treatment of many diseases, including Alzheimer's and cancer. With their ability to revolutionize development of advanced therapeutics, biomarkers have become essential tools.

Dr. Tanja Schubert, my colleague at Bioclinica Lab where molecular markers is the focus of our work, and I recently co-authored an article for EBR in the April 2017 issue. We begin the article taking a look at biomarkers'growing role in clinical trials across the drug development spectrum from target identification and preclinical tests through Phase 1 studies into post-marketing.

During fact-finding, we came across a report showing about 12 percent of all trials registered in 2013 included biomarkers with outcome measures and/or inclusion criteria. These biomarkers are primarily used in Phase 2 studies, helping to prove that the investigated product has the expected biological effect. As far as Phase 1 trials where safety and tolerability of a new investigational drug is assessed, biomarkers serve as a starting point to identify the most valuable biomarkers for a subsequent Phase 2 study. And over in Phase 3 studies where well-developed and characterized biomarkers are used - they very often prove to be those selected during Phase 2.

Biomarkers Categories
Next we take a look at the different categories of biomarkers as defined by the FDA-NIH Biomarker Working Group. We currently have seven biomarkers categories. Can you name them all?

  • Diagnostic
  • Monitoring
  • Pharmacodynamic (PD)/response
  • Predictive
  • Prognostic
  • Safety
  • Susceptibility/risk

Biomarkers in Precision Medicine
Precision medicine is a particularly exciting area in which progress is being made in a number of areas like companion diagnostics. Biomarkers have contributed to advancement of precision medicine and continue to bring discoveries on what seems to be a daily basis. Companion biomarkers, with their ability to predict response to a specific therapy help to classify patients into responders and non-responders. Usually co-developed with drugs, companion biomarkers provide essential information on the safe use of therapies.

Biomarker Validation and Qualification
Also in the article we take a look at biomarker validation and qualification, how assessed and how performance characteristics of the assay are measured.

You can find out more on this and the exciting work going on in biomarkers in the EBR article which can be accessed here.  Happy reading!

Preview Bioclinica Lab
If you'd like to preview our capabilities here, visit Bioclinica Lab where you can explore what we do, how we do it and our growing biomarkers menu. If you have a specific question please take a moment to submit an online contact request form here, and Dr. Schubert or myself will get back with you.

This is an area we're passionate about, and we'd love to hear from you as to what you're seeking to achieve by using biomarkers and how we may support your efforts.

Category: 

EBR Essential Tools Article

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

NJ Statewide Career & Internship Fair is Friday, April 28! Talk w @BioclinicaJobs Proj Mgmt, BD, CDM, IT. Details… https://t.co/27LdT00OEo
bioclinica (3 hours ago)
eHealth Solutions president Mukhtar Ahmed is speaking at #Phorum17 on Apr. 27 https://t.co/OaBPodxZBF https://t.co/VO6GKV0a8v
bioclinica (4 hours ago)
Global Head of Risk-Based Monitoring Kristin Mauri on #RBM essential capabilities. Read the blog here https://t.co/z3yUGZqOzH
bioclinica (9 hours ago)
Guest column by Nancy Bradish Myers & Anne McNickle on the White House deregulatory landscape @MedDeviceOnline… https://t.co/LlCJtAPpWz
bioclinica (9 hours ago)
Kicking off day 2 Clinical Trial Innov. Summit! Patient recruitment, RBM, technology-enabled #ClinicaTrials r hot t… https://t.co/IoynV539R9
bioclinica (11 hours ago)
Join us in Philly nxt wk at #Biomarkers & Immuno #Oncology World Congress! Happy to answer Qs in any of these areas https://t.co/fJ5mVAfQTe
bioclinica (Yesterday)

Latest Blogs: